AstraZeneca Pharma India Limited
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.
What AstraZeneca files
- Others66
- Important50
- Updates36
- Board Meeting7
- Investor Meet3
- Dividend/Bonus3
AstraZeneca Pharma India secured an independent ESG rating of 64 from Crisil ESG Ratings. This external assessment, based on public information, offers insights into the company's environmental, social, and governance standing.
AstraZeneca Pharma India independently received an ESG rating of 57 from Crisil ESG Ratings. This external assessment, based on public data, highlights the company's environmental, social, and governance profile.
AstraZeneca Pharma India reported 30% revenue growth to ₹682.8 Cr, with ₹51 Cr profit before tax. Performance was driven by core therapy areas. The company strengthened its portfolio with key regulatory approvals and strategic initiatives like the Telangana AI-enabled lung cancer screening MoU.
AstraZeneca Pharma India secured approval to market Enhertu for an additional HER2-positive breast cancer indication. This expands the drug's potential market in India, signaling future revenue growth opportunities.
AstraZeneca Pharma India gets approval to import and market Trastuzumab Deruxtecan (Enhertu®) for expanded use in HER2-positive Stage II/III breast cancer. This development boosts the drug's market scope in India.